Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Cellular adoptive immunotherapy uses a person's white blood cells that are treated
in the laboratory to stimulate the immune system in different ways and stop tumor cells from
growing. Aldesleukin may help the laboratory-treated white blood cells stay in the body
longer. Drugs used in chemotherapy, such as zoledronic acid, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Giving cellular adoptive immunotherapy together with interleukin-2 and zoledronic acid may
kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects of giving cellular adoptive
immunotherapy together with aldesleukin and zoledronic acid and to see how well it works in
treating patients with stage IV kidney cancer and lung metastases.